Nuveen’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-404,020
| Closed | -$6.11M | – | 3300 |
|
|
2022
Q3 | $6.11M | Sell |
404,020
-45,292
| -10% | -$526K | ﹤0.01% | 1781 |
|
|
2022
Q2 | $3.37M | Buy |
449,312
+64,974
| +17% | +$458K | ﹤0.01% | 2177 |
|
|
2022
Q1 | $3.21M | Buy |
384,338
+4,069
| +1% | +$31.4K | ﹤0.01% | 2286 |
|
|
2021
Q4 | $2.67M | Buy |
380,269
+6,410
| +2% | +$67.1K | ﹤0.01% | 2425 |
|
|
2021
Q3 | $4.26M | Sell |
373,859
-54,778
| -13% | -$801K | ﹤0.01% | 2303 |
|
|
2021
Q2 | $6.86M | Buy |
428,637
+66,692
| +18% | +$1.14M | ﹤0.01% | 2083 |
|
|
2021
Q1 | $6.47M | Sell |
361,945
-44,788
| -11% | -$774K | ﹤0.01% | 2038 |
|
|
2020
Q4 | $5.5M | Sell |
406,733
-191,751
| -32% | -$2.32M | ﹤0.01% | 2025 |
|
|
2020
Q3 | $7.04M | Buy |
598,484
+11,794
| +2% | +$144K | ﹤0.01% | 1735 |
|
|
2020
Q2 | $8.66M | Buy |
586,690
+78,123
| +15% | +$1.16M | ﹤0.01% | 1576 |
|
|
2020
Q1 | $6.87M | Buy |
508,567
+249,703
| +96% | +$4.74M | ﹤0.01% | 1531 |
|
|
2019
Q4 | $6.26M | Buy |
258,864
+48,886
| +23% | +$1.01M | ﹤0.01% | 1867 |
|
|
2019
Q3 | $4.04M | Buy |
209,978
+12,888
| +7% | +$295K | ﹤0.01% | 2069 |
|
|
2019
Q2 | $5.82M | Buy |
+197,090
| New | +$7.59M | ﹤0.01% | 1893 |
|
|
2017
Q2 | – | Sell |
-11,661
| Closed | -$529K | – | 1354 |
|
|
2017
Q1 | $529K | Sell |
11,661
-4,321
| -27% | -$193K | ﹤0.01% | 1145 |
|
|
2016
Q4 | $605K | Buy |
15,982
+480
| +3% | +$18.2K | ﹤0.01% | 1280 |
|
|
2016
Q3 | $585K | Buy |
+15,502
| New | +$342K | ﹤0.01% | 1214 |
|
Nuveen's AERI Position: Q4 2022 in Review
Nuveen sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 404,020 shares — an estimated $6.11M sold.
Nuveen first reported a position in AERI in Q3 2016 and held it in 17 quarters. The position peaked at $8.66M in Q2 2020. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Nuveen reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Nuveen sold 404,020 Aerie Pharmaceuticals shares in Q4 2022, an estimated $6.11M.
- Nuveen first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 17 quarters.
- Nuveen's Aerie Pharmaceuticals position peaked at $8.66M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Nuveen's 13F filing for Q4 2022, filed 14 Feb 2023.